Triple negative breast cancer is defined by combined lack of expression of the hormone receptors ESR1, PGR and the growth factor receptor HER2; thus, endocrine therapy and trastuzumab are generally not considered viable therapies for patients with TNBC (1-5). We recently utilized whole transcriptome technologies to define the full complement of differentially expressed kinases and phosphatases in HER2+ breast cancer: in the primary tumor, and in metastasis to the CNS (6-8). Measuring total transcription with RNA-sequencing and microarray in cancer based on quantitative expression of a defined biomarker or the normal tissues from which they are derived enables rational design and development of novel chemotherapies with optimized therapeutic index (9). Here we utilize whole transcriptome technologies (10, 11) to measure total transcription in the primary tumors of humans with androgen receptor-positive TNBC. We describe a therapeutic target that is up-regulated and differentially expressed in TNBCs that express the androgen receptor, DUSP4, as a candidate therapeutic target for the medical management of the primary tumor in AR+ TNBC.